LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in Lo...

AC Immune (NASDAQ: ACIU ): Q3 Non-GAAP EPS of CHF0.26; GAAP EPS of CHF0.25 beats by CHF0.30 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...

 CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical...